Niskayuna, NY, United States of America

Douglas Gregory Stafford

This inventor holds 15 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Syk Inhibitors. Top assignees: Gilead Connecticut, Inc., Activbiotics, Inc., Activbiotics Pharma, LLC. Active years: 2007-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Douglas Gregory Stafford. Retrieved from https://idiyas.com/inventor/douglas-gregory-stafford

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15 

% Patents Active = 53.3


 

Average Co-Inventor Count = 8.1

ph-index = 8

Forward Citations = 204(Granted Patents)


Company Filing History:


Years Active: 2007-2018

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Syk Inhibitors
Imidazo[1,2-a]Pyrazines
Pyrazolo[1,5-a]Pyrimidines
Rifamycin Analogs
Substituted Amides
Substituted Pyrazinones
Chemical Compounds
Drug Development
Pharmaceutical Research
Medicinal Chemistry
Therapeutic Agents
Biological Activity
15 patents (USPTO):Explore Patents

Certainly! Here is an article about inventor Douglas Gregory Stafford:

Title: Innovator Spotlight: Douglas Gregory Stafford Pushing Boundaries in Inventions

Introduction: Douglas Gregory Stafford, a pioneering inventor hailing from Niskayuna, NY, is a true visionary in the realm of innovation. With a track record of 15 patents to his name, Stafford's passion for pushing the boundaries of what is possible has solidified his position as a trailblazer in the world of inventions.

Latest Patents: Among Stafford's latest patents is his groundbreaking work on "Substituted imidazo[1,2-a]pyrazines as Syk inhibitors." These innovative pharmaceutical compositions and methods of treatment have shown promise in addressing diseases and disorders responsive to the inhibition of Syk activity. Additionally, his compound "6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine" has demonstrated potential in treating conditions such as B-cell lymphomas and inflammatory diseases.

Career Highlights: Stafford's illustrious career has seen him contribute significantly to companies such as Gilead Connecticut, Inc. and Activbiotics, Inc. His innovative spirit and dedication to transformative research have been instrumental in driving advancements in healthcare and beyond.

Collaborations: Throughout his career, Stafford has collaborated closely with esteemed colleagues such as Scott A Mitchell and Kevin S Currie. Together, they have worked tirelessly to bring cutting-edge inventions to fruition and make a lasting impact on the field of biopharmaceuticals.

Conclusion: In conclusion, Douglas Gregory Stafford's unwavering commitment to innovation and his relentless pursuit of groundbreaking inventions have cemented his status as a true pioneer in the world of patents and discoveries. His ongoing contributions to the field continue to inspire and shape the future of revolutionary treatments and technologies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…